Ipsen CEO To Feed Group's Three Therapeutic Engines Fresh Assets In 2018
CEO David Meek Says Ipsen has more than $1bn for M&A use to expand its product line in oncology, neuroscience and rare diseases.
You may also be interested in...
Merrimack Pharmaceuticals has ended development of its experimental treatment for pancreatic cancer after it failed to meet the main and secondary goals in a mid-stage trial.
In a video interview at the Biotech Showcase, Exelixis CEO Michael Morrissey discusses the recent launch of cabozantinib in first-line renal cell carcinoma and looks ahead to filing soon in liver cancer.
Ipsen's new CEO David Meek has conducted the French company's biggest ever deal by acquiring Onivyde for pancreatic cancer from Merrimack Pharmaceuticals, and believes Ipsen will turn Onivyde's fortunes around.